{"ticker": {"uuid": "b0b3f73d-3d9d-449a-adf1-a313501c32c5", "symbol": "OKUR", "name": "OnKure Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to revenue forward of OnKure Therapeutics, Inc. \u2013 NASDAQ:OKUR", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQMkNWMDJXTzgyejBUdW14QkJ1aExPUDhwRnlTTV9JelZXYlZXZElvRWpRRkFmbWdFY3M0blR3MlQ1ZnNjM191S0RyVC0zYldTOVNfckpPaDdtN3Y0MEp1blBoSlJtMVdFSXVEY2hwbUwwNEYtbFJKbmhyNG1YVURoZy1nci1WWndtZjJsRWVvQ2F1aGZqd1dKLUJqTHE3WEl4LTlvRnY3TURpa1c5?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T22:52:35+00:00", "published_display": "15 Jul 2026 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Spotlights Allosteric PI3K\u03b1 Drugs as 2027 IND Targets Near", "summary": "", "url": "https://finance.yahoo.com/m/f6eb474d-b3f3-3a50-8484-b9e9707b0c4d/onkure-therapeutics.html", "source_name": "MarketBeat", "published_at": "2026-07-15T17:02:37+00:00", "published_display": "15 Jul 2026 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVHVvOXdsakJYVGlsU1hXM1lOTnFqeV9udFktc2FCSDZQSXF0LVJLUERIbU5zODlURkJzTV9KWm40X1dyQjQwLUlUQzNNSXVjRkVYeXlfM1ZRQnZ6bjh5a1RfVVowSDVMbHYwSHFFWjFBd2wyNlAwamZOUzQ0eG9GRkdRekQ2QUttcU9oc056M05UWW1oMWNPNXpkQjlhaUhzanluWmRfNlAxRTdnU2RJT29uaEt0Unl5bk84ZTduRThRNmFOVnlWdWp3QmJ0RjVGR0RYTFlMRGF3enlQQWFvYmRPLTN6RlF30gHuAUFVX3lxTE1vcks3VzhWX1dPajlyRFhPdlNQRUJ0RzNManBKeFFOZTNLaHhuUEVwbFNCRENuT1V5ZlpsTHIwQUd0d2FvUHh5RHJQUTJtWVpSMFAwVGlNTUhWeFB2a1lpTWhsaXNJeHpyX2JYVUtSVjEtQS10QjNTWl94Tl8tRk5XT2lseFFrVnFRSmFTWnNFVllYXzk0VGlrc2hTTU5mSEp5WWVMN2V1ckFvTmhzcEFpdEQxS1o2RlhrVnUxQUNoR1hlNDNxLVFhQWx2UmhCNGRwTjE1cW9FN2ZQN0pxZlowQ1c0Q0hwN1liRGpVWWc?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T10:28:42+00:00", "published_display": "14 Jul 2026 10:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBPVWMxR3FHUjJHdWlIT3BVLW9Tay1MX0pRbjFvVUJORGxkd2V1ZkpzYmc5eU9yM3lyT1JDYXlDMExKLVl2RlNjTUpaLWZRU1hINXRCN1dlSV9FRmU5M0NyOExBOA?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T02:00:13+00:00", "published_display": "09 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3K\u03b1 Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/onkure-therapeutics-host-virtual-kol-120000522.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T12:00:00+00:00", "published_display": "02 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 3000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUDdiX0QtRlJOZnNPWF9QZVNKMnFlc0ptZTJrOVhGTVkxdGZmLWNYSWpURUVJNkJMNHpuZkhfS2pVbGVQQzdUZXF5cTlsVEQxay1mODlDanBCOHgtaE9XTUhPRFV1UFphRVE2OTFoT2JySDVtY0VCdTd4czZGVjBSTXhmeDUyNjhDcnowVzlCcXJscVJBbFB3QVJEUGZkWjlScy03SVNkSmZDZzlvaTU5YWh1VTFNQ1lvQ1E?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) Gains 2.13% as Stock Holds Above Key Support - ETF Inflow Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOS1dtcEJKcGloZGl2NkhVbTFWRFMyQ2VmMGpaSExoTWdvcjRoN1lVdXoxMmFsZ093NFJnUHR1Ulk4cEcwOTVhNVZybW9EVmpBaXg3M0pDZW5IU0lrUU44b29Fcmx5bWI2TDc3MC1qbTltQ0tLMTZ3TE8zLS1CbHlmdTc1Nk8wdklwVkZqSF90Q2hkSmdJaDMzM29mOEIzcllfVU5lbzBYdGZ0WHlrdjVvcko2aHQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Onkure Therapeutics Inc For: 24 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOcjRXVFNRb2toMTZFNWZfQ2IxVzFiNkRkRnNodklXN0s1Q1BadG1ucnlKYTVuNjdvVjJ1M1BfSmpocjMyUk1ldlJlcExOOUpsU2J3cjVOTkFDUEpFLTk4X00zZVpKTWVhbzJIa1pxbGd5RmpQT2xLQm1MN2NvNURjOFg2S0ZsaE9mTGllT1h5eFExa25TckZQUy1Obkp1MDgxWlVNS3h3?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-24T23:46:00+00:00", "published_display": "24 Jun 2026 23:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) CFO auto-sells shares to cover RSU tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObURmX0NSeE5FUjZtcmZ5SHhreFpwbGp1TmVrYzdwRkZvc0NuMFNMWjlyallhb2NQWEpuQUszOTFwNGRmRzdIeElQS0tqM2d2dTdLSmVRdm5GWHRoWEZEc2FMNS1OWnpPVUh1SWhseWhGdTB6NnZ1c084Z1hjc2J0blhJSEVSUDkxQnBlbmRmNS1hRWtoSEQ2YWxoMTRUMTdnbkZibDRHc0dlOER2TWJYMDJrTHJ1R3BEY2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics president and CEO sells $378 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxORmxncGFUNzlZZl81c081RVozeHNCV3JMVzJ3eERDSlFXdTZzZTllM3ZDamN5YWVGZlMyUWxOOUQ0bzlfX3FEVzJPck9TSnM4ajU5aWpxeVZPYmFzdWUtRlo1cURmejR0UzNzQlRBWWZnT0hET25jOUltYXI1WUJEZThEY25EaU9KLUtmV3hLay01Q1JKT0NPT1p6Yjk4djM1ZHZsWF9wT3hGOEM4eFJ4UlpIaFRWOUtRLTNtRDhB?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - Earnings Season Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQVWZZeHZPd0xiRUhRSWt6YUIyVVpXT0RuMmVENUVwblc5b3F6emI3UmtmaUdoZm1paTNOdFpFRkpjSWpoODY3NExUUEZWMTM0R1FVRTJVZWVLOGlXM2c4ZzZaNkJEYi1GSXQ5TUJzTk5CWHdDaDNpb2pxc0xoZ0xERkl1ZW10cFpaVHN5bXNCZnV6c3BMemhOVS1kUE9ZUE81Qk9uVlljSG1RSHp1UjVVVFBPRWFIWU1MWm5aTzRxeks0bk4ydWx1dVQ0aW82NmxsR0hVZkZSaTZ2LWY5RUpwMW1qOHBQck0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxPWFdiQXhmRWFNN2pKV3dCa1paVW9jMGZGWFFuOEQyekFsam1kWTFPUThjbUNoTDNZcVlSUm5YdFN5M2NUOXpvd1VpUzEyZUN2NHgyaWNCamRxWkRhemJ4OHBpT0RCVUtyUFRJTXFaQXh3b1Y5WnhvZGw3RkF2YjJSVDdqM2djSy1odno4bnFDMlFQLVVvQXZ1anVaUE5OY1dzaXFYelV1RHpOT1RaZTE2d05OOFNkZWo4cFRRZVFHSHFMb2pGbHRXTmUyS1pCR21CaWxyeFJLV2hlR1BDc2ZqNWVKNnhNQ2FWaVR1NUh4YjhmWHpVWDdabFBLdUwtQnNWcXFId0kyb1RGMkMyQ1ZpSXk0SkNhUWlQR0JSQnZjaW5NMzFPNzNuag?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/onkure-therapeutics-reports-first-quarter-200500389.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T20:05:00+00:00", "published_display": "05 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "OnKure Therapeutics (NASDAQ: OKUR) registers 36.1M shares for resale", "summary": "OnKure Therapeutics (NASDAQ: OKUR) has filed an S-3 shelf registration statement to allow selling shareholders to resell up to 36.1 million shares of Class A common stock. This includes 26.7 million existing shares and 9.4 million shares issuable upon the exercise of pre-funded w", "url": "https://www.stocktitan.net/sec-filings/OKUR/s-3-on-kure-therapeutics-inc-shelf-registration-statement-836b252769ca.html", "source_name": "Stock Titan", "published_at": "2026-04-24T20:10:00", "published_display": "24 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should I buy OnKure Therapeutics, Inc. (OKUR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1UTzN1Z3dfMW4wdlRQc3NMMkdBdVFhbGQ4ZVIzaFBFTndSS1Q4a1UxclBLVUJIWm5NbXRTUExmZTl4M0RuS1JiclJfOTZwamJiWDQ1em9SMVJBc093SmZTZkFoNVhoSTkxdVdkdg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Access Industries (OKUR) discloses 19.99% OnKure stake and board right", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOTkVic2x0VExUdTlVQ3ZOVl9uRGFCOTRyS1ZvQnRiSHVDY2pFVzZ0V2E5Y0VtXzFzcUVqbHY1LWxSN3owNFRXaXIxSHk0YlRQX0ZTRFMtWVFVRkFLUGNYOTgyTHhqYTRqY3cxMXl2VXR4SzZUZ1dIRmZPaWsyTVNIdEJYLVFFMTRSUDR3RXdEMUtjOThLb2tSV2dWSTBCQmI0a0U4c3ZrcWdLU0NubDhraFNyVmhxWWxaalgzU01TS3VTTVh4OElESlhlOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Breast cancer, vascular drug push gets OnKure $150M and a 2029 runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPaDlFYXVfU0VPZTNzN2RrWEM0amZNLVFUaGxtcWJBU3ZiMHd1amNPRDNGM0tQd2ZRd2lOa3dNVlVHdkZjODIxNTZLbnJxZHdWdUd4dHRvMDZEeWZtZGxzX2c3TTVmTWV1R0ZDSngzRk9uMUxieEVfdzRoeVRfSlUwbGVQdG82M3VWcFlzMUpYTXA1WDZwS0stZ3kyYzI2Q2ZLY1piSUJnbFZucF9TNW1NNVN6UlIwQlAzbWR4RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3K\u03b1 Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wJBVV95cUxNLTNiSkt2XzdURmVHR3pfRDhFX3FTeTREYW9RMjlwdFl2ZUw4VGUyOTNXVVlsYUpnc2pQQTlfdHRlemMyMmdjWnVxZlJvRkhJVXJxcjJoWXoybmNwOHViaEdFVHNzdldtcWpZVmNoMHNuSU15ZndsQ2F3bzMwMS0yRlBhUV9XbGFuMW05YVlJQ1VhV1FUNW11Ql9UOFFPYXdpVUlsN0swZGpZY015bmlEdTdWQmxCc0NrM0VwVFZEZ0lHZWlUbEVaYmhHVHJFbnVqdTV2LU41RUctX010T3hWRTVFcER3SVpjTUd5eWZmd3FjZHZJYmtZdUlmX2FqcWdwd2JJSDZWWnQxSXNGY3hUSkRlZ3ZrN2lHaUlmT3doWXdjNVNqQWJmS3o5Z3pnWDNSTkZIRjBIZm5MM3pqRmNObDdfb1pHZ3ZYUDVmenpBZ0tWTnJZdnVsanBlTkQ1V2FNYzlCeGF0UFM0TldFYlF4TW01Yw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Stock Fluctuates With Market Shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPM3NMOENxZDV1emNZeVZOOU13XzhpQWVJcE5ZNkc2YnNLVzFHY2tua2lfRTlRRFhjNXlhYU5DeDJpZm45TlNuUzdYdF91b1YzRmJUcE9MaTh2ajI0YllzaHVNLW9yS2ZuemVjckh3T2RnVGE3MmRtQUc3VjZYdEs0RUl3?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics CEO Saccomano sells $357 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOR1NsZXFXNERBRm1LTlhVYi02cFh4V2NucENqbVlVWlpVSWt3bmctY2kxcXctcldnRGFUN0E3bTFHemdHYUpDSzdhQjF5ZGJzRzZzUFd5V2lCQlNTVUZQbHJsZVBhWE9OeFVCMTNXVGYybVJzT0VqRUs5V25QcDJtQmIxVVpiU3pYVjBTZi1RQzM2eHY3OHJXTEoyMUg5ZDNmZ0tMd1Y2RzFYYkdDN1VSRUlWZ2xWMExB?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million", "summary": "OnKure Therapeutics has completed its merger with Reneo Pharmaceuticals and a concurrent $65 million private placement, with the combined company now trading on Nasdaq as OKUR. This transaction provides OnKure with approximately $139 million in cash, extending its operational run", "url": "https://www.stocktitan.net/news/RPHM/on-kure-announces-closing-of-merger-with-reneo-pharmaceuticals-and-1ztns3mv950k.html", "source_name": "Stock Titan", "published_at": "2026-03-03T02:52:38", "published_display": "03 Mar 2026 02:52", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is OnKure Therapeutics (NASDAQ:OKUR) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-23T07:00:00+00:00", "published_display": "23 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKUR Stock Price, News & Analysis", "summary": "OnKure Therapeutics (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on precision medicines for cancers driven by PI3K\u03b1 mutations, with its lead candidate OKI-219 in Phase 1 clinical trials for advanced solid tumors. The company is also developing a broader PI", "url": "https://www.stocktitan.net/overview/OKUR/", "source_name": "Stock Titan", "published_at": "2025-05-06T00:08:36", "published_display": "06 May 2025 00:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for OnKure Therapeutics, Inc. (OKUR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5VQ3hJT3lUV2hNa3dWUTdQQTdmV1ZnQS1iWXRWemF6TFVidkZZd2pEc3NDeUlTVE1aN2J0RHJvaXVkV2FETC1zZjV1T1R4MXFmUGJZQ1c3R3NDeDhjNzZsNTJTR054UkVHVTV6NjZHRk8xcm90WGx6aQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-10-18T05:50:57+00:00", "published_display": "18 Oct 2024 05:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9rYTE5a0p6WThQN2VCRnk1TFQ4THRDaWVPaHNvYjE2NWFuOFVaNndxRThkRTNpQmtadGJvN29JQjBhSkszeXoyNXhyQ0ppdWY1ekIxR0RSTnVEUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-10-10T15:08:00+00:00", "published_display": "10 Oct 2024 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKUR Stock Price and Chart \u2014 NASDAQ:OKUR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Ecm8taEJSYzRfaGpCX0JyNTJQcVVuZC1Oa0FTZVdFMjRDVDN0dkJ6ZDZ1TG1SbXZXeVJjUUM0NFlsYnRsbTR6dXc2X1hpV29EYWZtRUpDYmlOMG1t?oc=5", "source_name": "TradingView", "published_at": "2024-10-07T13:49:40+00:00", "published_display": "07 Oct 2024 13:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure and Reneo Pharmaceuticals complete merger", "summary": "OnKure and Reneo Pharmaceuticals have successfully completed their merger, with the combined company now operating as OnKure Therapeutics. The new entity's shares will trade on Nasdaq under the ticker \"OKUR\" following an all-stock deal and a $65 million private placement. The mer", "url": "https://finance.yahoo.com/news/onkure-reneo-pharmaceuticals-complete-merger-083240643.html", "source_name": "Market source", "published_at": "2024-10-07T07:31:36", "published_display": "07 Oct 2024 07:31", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure", "summary": "Reneo Pharmaceuticals announced that its stockholders approved all proposals for the merger with OnKure, Inc., which is expected to close around October 4, 2024. Following the merger, the combined company will be named OnKure Therapeutics, Inc., trade under the ticker \"OKUR\" on N", "url": "https://www.globenewswire.com/news-release/2024/10/03/2957405/0/en/reneo-pharmaceuticals-announces-stockholder-approval-of-merger-with-onkure.html", "source_name": "GlobeNewswire", "published_at": "2024-10-02T23:11:15", "published_display": "02 Oct 2024 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results", "summary": "Reneo Pharmaceuticals reported a net loss of $5.4 million for the second quarter of 2024, a significant improvement from $19.5 million in the same period of 2023. The company is in the process of merging with OnKure, Inc. in an all-stock transaction, which is expected to close in", "url": "https://finance.yahoo.com/news/reneo-pharmaceuticals-reports-second-quarter-113500358.html", "source_name": "Market source", "published_at": "2024-08-13T20:39:09", "published_display": "13 Aug 2024 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger", "summary": "Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals on intellectual property matters concerning its definitive merger agreement with OnKure, Inc. This all-stock transaction will combine the two biopharmaceutical companies with a focus on advancing OnKure\u2019s oncology pip", "url": "https://www.wsgr.com/en/insights/wilson-sonsini-advises-reneo-pharmaceuticals-on-ip-matters-related-to-onkure-merger.html", "source_name": "Wilson Sonsini", "published_at": "2024-05-15T15:09:12", "published_display": "15 May 2024 15:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure hitches Reneo's ride to Nasdaq in merger, with $65M PIPE to boot", "summary": "OnKure Therapeutics has merged with Reneo Pharmaceuticals in a reverse merger, bringing $120 million and a breast cancer treatment pipeline to the Nasdaq under the ticker \"OKUR.\" The deal includes a $65 million PIPE financing, with Reneo needing to maintain $55 million in cash, p", "url": "https://www.fiercebiotech.com/biotech/onkure-hitches-reneos-ride-nasdaq-65m-pipe-boot", "source_name": "Fierce Biotech", "published_at": "2024-05-13T10:36:00", "published_display": "13 May 2024 10:36", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reneo Pharmaceuticals and OnKure Announce Proposed Merger", "summary": "Reneo Pharmaceuticals and OnKure, a clinical-stage biopharmaceutical company, have announced a definitive merger agreement in an all-stock transaction. The combined entity, to be named OnKure Therapeutics, Inc., will focus on advancing OnKure's oncology pipeline, including its le", "url": "https://finance.yahoo.com/news/reneo-pharmaceuticals-onkure-announce-proposed-113500103.html", "source_name": "Market source", "published_at": "2024-05-13T08:10:03", "published_display": "13 May 2024 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to revenue forward of OnKure Therapeutics, Inc. \u2013 NASDAQ:OKUR", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQMkNWMDJXTzgyejBUdW14QkJ1aExPUDhwRnlTTV9JelZXYlZXZElvRWpRRkFmbWdFY3M0blR3MlQ1ZnNjM191S0RyVC0zYldTOVNfckpPaDdtN3Y0MEp1blBoSlJtMVdFSXVEY2hwbUwwNEYtbFJKbmhyNG1YVURoZy1nci1WWndtZjJsRWVvQ2F1aGZqd1dKLUJqTHE3WEl4LTlvRnY3TURpa1c5?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T22:52:35+00:00", "published_display": "15 Jul 2026 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Spotlights Allosteric PI3K\u03b1 Drugs as 2027 IND Targets Near", "summary": "", "url": "https://finance.yahoo.com/m/f6eb474d-b3f3-3a50-8484-b9e9707b0c4d/onkure-therapeutics.html", "source_name": "MarketBeat", "published_at": "2026-07-15T17:02:37+00:00", "published_display": "15 Jul 2026 17:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxQVHVvOXdsakJYVGlsU1hXM1lOTnFqeV9udFktc2FCSDZQSXF0LVJLUERIbU5zODlURkJzTV9KWm40X1dyQjQwLUlUQzNNSXVjRkVYeXlfM1ZRQnZ6bjh5a1RfVVowSDVMbHYwSHFFWjFBd2wyNlAwamZOUzQ0eG9GRkdRekQ2QUttcU9oc056M05UWW1oMWNPNXpkQjlhaUhzanluWmRfNlAxRTdnU2RJT29uaEt0Unl5bk84ZTduRThRNmFOVnlWdWp3QmJ0RjVGR0RYTFlMRGF3enlQQWFvYmRPLTN6RlF30gHuAUFVX3lxTE1vcks3VzhWX1dPajlyRFhPdlNQRUJ0RzNManBKeFFOZTNLaHhuUEVwbFNCRENuT1V5ZlpsTHIwQUd0d2FvUHh5RHJQUTJtWVpSMFAwVGlNTUhWeFB2a1lpTWhsaXNJeHpyX2JYVUtSVjEtQS10QjNTWl94Tl8tRk5XT2lseFFrVnFRSmFTWnNFVllYXzk0VGlrc2hTTU5mSEp5WWVMN2V1ckFvTmhzcEFpdEQxS1o2RlhrVnUxQUNoR1hlNDNxLVFhQWx2UmhCNGRwTjE1cW9FN2ZQN0pxZlowQ1c0Q0hwN1liRGpVWWc?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T10:28:42+00:00", "published_display": "14 Jul 2026 10:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in OnKure Therapeutics, Inc. Class A Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBPVWMxR3FHUjJHdWlIT3BVLW9Tay1MX0pRbjFvVUJORGxkd2V1ZkpzYmc5eU9yM3lyT1JDYXlDMExKLVl2RlNjTUpaLWZRU1hINXRCN1dlSV9FRmU5M0NyOExBOA?oc=5", "source_name": "TradingView", "published_at": "2026-07-09T02:00:13+00:00", "published_display": "09 Jul 2026 02:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3K\u03b1 Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/onkure-therapeutics-host-virtual-kol-120000522.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T12:00:00+00:00", "published_display": "02 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics, Inc.(NasdaqGM: OKUR) added to Russell 3000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNUDdiX0QtRlJOZnNPWF9QZVNKMnFlc0ptZTJrOVhGTVkxdGZmLWNYSWpURUVJNkJMNHpuZkhfS2pVbGVQQzdUZXF5cTlsVEQxay1mODlDanBCOHgtaE9XTUhPRFV1UFphRVE2OTFoT2JySDVtY0VCdTd4czZGVjBSTXhmeDUyNjhDcnowVzlCcXJscVJBbFB3QVJEUGZkWjlScy03SVNkSmZDZzlvaTU5YWh1VTFNQ1lvQ1E?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) Gains 2.13% as Stock Holds Above Key Support - ETF Inflow Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOS1dtcEJKcGloZGl2NkhVbTFWRFMyQ2VmMGpaSExoTWdvcjRoN1lVdXoxMmFsZ093NFJnUHR1Ulk4cEcwOTVhNVZybW9EVmpBaXg3M0pDZW5IU0lrUU44b29Fcmx5bWI2TDc3MC1qbTltQ0tLMTZ3TE8zLS1CbHlmdTc1Nk8wdklwVkZqSF90Q2hkSmdJaDMzM29mOEIzcllfVU5lbzBYdGZ0WHlrdjVvcko2aHQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Onkure Therapeutics Inc For: 24 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOcjRXVFNRb2toMTZFNWZfQ2IxVzFiNkRkRnNodklXN0s1Q1BadG1ucnlKYTVuNjdvVjJ1M1BfSmpocjMyUk1ldlJlcExOOUpsU2J3cjVOTkFDUEpFLTk4X00zZVpKTWVhbzJIa1pxbGd5RmpQT2xLQm1MN2NvNURjOFg2S0ZsaE9mTGllT1h5eFExa25TckZQUy1Obkp1MDgxWlVNS3h3?oc=5", "source_name": "Investing.com UK", "published_at": "2026-06-24T23:46:00+00:00", "published_display": "24 Jun 2026 23:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) CFO auto-sells shares to cover RSU tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObURmX0NSeE5FUjZtcmZ5SHhreFpwbGp1TmVrYzdwRkZvc0NuMFNMWjlyallhb2NQWEpuQUszOTFwNGRmRzdIeElQS0tqM2d2dTdLSmVRdm5GWHRoWEZEc2FMNS1OWnpPVUh1SWhseWhGdTB6NnZ1c084Z1hjc2J0blhJSEVSUDkxQnBlbmRmNS1hRWtoSEQ2YWxoMTRUMTdnbkZibDRHc0dlOER2TWJYMDJrTHJ1R3BEY2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics president and CEO sells $378 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxORmxncGFUNzlZZl81c081RVozeHNCV3JMVzJ3eERDSlFXdTZzZTllM3ZDamN5YWVGZlMyUWxOOUQ0bzlfX3FEVzJPck9TSnM4ajU5aWpxeVZPYmFzdWUtRlo1cURmejR0UzNzQlRBWWZnT0hET25jOUltYXI1WUJEZThEY25EaU9KLUtmV3hLay01Q1JKT0NPT1p6Yjk4djM1ZHZsWF9wT3hGOEM4eFJ4UlpIaFRWOUtRLTNtRDhB?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - Earnings Season Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQVWZZeHZPd0xiRUhRSWt6YUIyVVpXT0RuMmVENUVwblc5b3F6emI3UmtmaUdoZm1paTNOdFpFRkpjSWpoODY3NExUUEZWMTM0R1FVRTJVZWVLOGlXM2c4ZzZaNkJEYi1GSXQ5TUJzTk5CWHdDaDNpb2pxc0xoZ0xERkl1ZW10cFpaVHN5bXNCZnV6c3BMemhOVS1kUE9ZUE81Qk9uVlljSG1RSHp1UjVVVFBPRWFIWU1MWm5aTzRxeks0bk4ydWx1dVQ0aW82NmxsR0hVZkZSaTZ2LWY5RUpwMW1qOHBQck0?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxPWFdiQXhmRWFNN2pKV3dCa1paVW9jMGZGWFFuOEQyekFsam1kWTFPUThjbUNoTDNZcVlSUm5YdFN5M2NUOXpvd1VpUzEyZUN2NHgyaWNCamRxWkRhemJ4OHBpT0RCVUtyUFRJTXFaQXh3b1Y5WnhvZGw3RkF2YjJSVDdqM2djSy1odno4bnFDMlFQLVVvQXZ1anVaUE5OY1dzaXFYelV1RHpOT1RaZTE2d05OOFNkZWo4cFRRZVFHSHFMb2pGbHRXTmUyS1pCR21CaWxyeFJLV2hlR1BDc2ZqNWVKNnhNQ2FWaVR1NUh4YjhmWHpVWDdabFBLdUwtQnNWcXFId0kyb1RGMkMyQ1ZpSXk0SkNhUWlQR0JSQnZjaW5NMzFPNzNuag?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/onkure-therapeutics-reports-first-quarter-200500389.html", "source_name": "GlobeNewswire", "published_at": "2026-05-05T20:05:00+00:00", "published_display": "05 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (NASDAQ: OKUR) registers 36.1M shares for resale", "summary": "OnKure Therapeutics (NASDAQ: OKUR) has filed an S-3 shelf registration statement to allow selling shareholders to resell up to 36.1 million shares of Class A common stock. This includes 26.7 million existing shares and 9.4 million shares issuable upon the exercise of pre-funded w", "url": "https://www.stocktitan.net/sec-filings/OKUR/s-3-on-kure-therapeutics-inc-shelf-registration-statement-836b252769ca.html", "source_name": "Stock Titan", "published_at": "2026-04-24T20:10:00", "published_display": "24 Apr 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy OnKure Therapeutics, Inc. (OKUR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1UTzN1Z3dfMW4wdlRQc3NMMkdBdVFhbGQ4ZVIzaFBFTndSS1Q4a1UxclBLVUJIWm5NbXRTUExmZTl4M0RuS1JiclJfOTZwamJiWDQ1em9SMVJBc093SmZTZkFoNVhoSTkxdVdkdg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Access Industries (OKUR) discloses 19.99% OnKure stake and board right", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOTkVic2x0VExUdTlVQ3ZOVl9uRGFCOTRyS1ZvQnRiSHVDY2pFVzZ0V2E5Y0VtXzFzcUVqbHY1LWxSN3owNFRXaXIxSHk0YlRQX0ZTRFMtWVFVRkFLUGNYOTgyTHhqYTRqY3cxMXl2VXR4SzZUZ1dIRmZPaWsyTVNIdEJYLVFFMTRSUDR3RXdEMUtjOThLb2tSV2dWSTBCQmI0a0U4c3ZrcWdLU0NubDhraFNyVmhxWWxaalgzU01TS3VTTVh4OElESlhlOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Breast cancer, vascular drug push gets OnKure $150M and a 2029 runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPaDlFYXVfU0VPZTNzN2RrWEM0amZNLVFUaGxtcWJBU3ZiMHd1amNPRDNGM0tQd2ZRd2lOa3dNVlVHdkZjODIxNTZLbnJxZHdWdUd4dHRvMDZEeWZtZGxzX2c3TTVmTWV1R0ZDSngzRk9uMUxieEVfdzRoeVRfSlUwbGVQdG82M3VWcFlzMUpYTXA1WDZwS0stZ3kyYzI2Q2ZLY1piSUJnbFZucF9TNW1NNVN6UlIwQlAzbWR4RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3K\u03b1 Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics Stock Fluctuates With Market Shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPM3NMOENxZDV1emNZeVZOOU13XzhpQWVJcE5ZNkc2YnNLVzFHY2tua2lfRTlRRFhjNXlhYU5DeDJpZm45TlNuUzdYdF91b1YzRmJUcE9MaTh2ajI0YllzaHVNLW9yS2ZuemVjckh3T2RnVGE3MmRtQUc3VjZYdEs0RUl3?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics CEO Saccomano sells $357 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOR1NsZXFXNERBRm1LTlhVYi02cFh4V2NucENqbVlVWlpVSWt3bmctY2kxcXctcldnRGFUN0E3bTFHemdHYUpDSzdhQjF5ZGJzRzZzUFd5V2lCQlNTVUZQbHJsZVBhWE9OeFVCMTNXVGYybVJzT0VqRUs5V25QcDJtQmIxVVpiU3pYVjBTZi1RQzM2eHY3OHJXTEoyMUg5ZDNmZ0tMd1Y2RzFYYkdDN1VSRUlWZ2xWMExB?oc=5", "source_name": "Investing.com", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million", "summary": "OnKure Therapeutics has completed its merger with Reneo Pharmaceuticals and a concurrent $65 million private placement, with the combined company now trading on Nasdaq as OKUR. This transaction provides OnKure with approximately $139 million in cash, extending its operational run", "url": "https://www.stocktitan.net/news/RPHM/on-kure-announces-closing-of-merger-with-reneo-pharmaceuticals-and-1ztns3mv950k.html", "source_name": "Stock Titan", "published_at": "2026-03-03T02:52:38", "published_display": "03 Mar 2026 02:52", "sentiment": "positive", "sentiment_pct": 76, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is OnKure Therapeutics (NASDAQ:OKUR) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-23T07:00:00+00:00", "published_display": "23 Jul 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKUR Stock Price, News & Analysis", "summary": "OnKure Therapeutics (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on precision medicines for cancers driven by PI3K\u03b1 mutations, with its lead candidate OKI-219 in Phase 1 clinical trials for advanced solid tumors. The company is also developing a broader PI", "url": "https://www.stocktitan.net/overview/OKUR/", "source_name": "Stock Titan", "published_at": "2025-05-06T00:08:36", "published_display": "06 May 2025 00:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for OnKure Therapeutics, Inc. (OKUR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE5VQ3hJT3lUV2hNa3dWUTdQQTdmV1ZnQS1iWXRWemF6TFVidkZZd2pEc3NDeUlTVE1aN2J0RHJvaXVkV2FETC1zZjV1T1R4MXFmUGJZQ1c3R3NDeDhjNzZsNTJTR054UkVHVTV6NjZHRk8xcm90WGx6aQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-10-18T05:50:57+00:00", "published_display": "18 Oct 2024 05:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure Therapeutics (OKUR) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9rYTE5a0p6WThQN2VCRnk1TFQ4THRDaWVPaHNvYjE2NWFuOFVaNndxRThkRTNpQmtadGJvN29JQjBhSkszeXoyNXhyQ0ppdWY1ekIxR0RSTnVEUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-10-10T15:08:00+00:00", "published_display": "10 Oct 2024 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OKUR Stock Price and Chart \u2014 NASDAQ:OKUR", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9Ecm8taEJSYzRfaGpCX0JyNTJQcVVuZC1Oa0FTZVdFMjRDVDN0dkJ6ZDZ1TG1SbXZXeVJjUUM0NFlsYnRsbTR6dXc2X1hpV29EYWZtRUpDYmlOMG1t?oc=5", "source_name": "TradingView", "published_at": "2024-10-07T13:49:40+00:00", "published_display": "07 Oct 2024 13:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure and Reneo Pharmaceuticals complete merger", "summary": "OnKure and Reneo Pharmaceuticals have successfully completed their merger, with the combined company now operating as OnKure Therapeutics. The new entity's shares will trade on Nasdaq under the ticker \"OKUR\" following an all-stock deal and a $65 million private placement. The mer", "url": "https://finance.yahoo.com/news/onkure-reneo-pharmaceuticals-complete-merger-083240643.html", "source_name": "Market source", "published_at": "2024-10-07T07:31:36", "published_display": "07 Oct 2024 07:31", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure", "summary": "Reneo Pharmaceuticals announced that its stockholders approved all proposals for the merger with OnKure, Inc., which is expected to close around October 4, 2024. Following the merger, the combined company will be named OnKure Therapeutics, Inc., trade under the ticker \"OKUR\" on N", "url": "https://www.globenewswire.com/news-release/2024/10/03/2957405/0/en/reneo-pharmaceuticals-announces-stockholder-approval-of-merger-with-onkure.html", "source_name": "GlobeNewswire", "published_at": "2024-10-02T23:11:15", "published_display": "02 Oct 2024 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results", "summary": "Reneo Pharmaceuticals reported a net loss of $5.4 million for the second quarter of 2024, a significant improvement from $19.5 million in the same period of 2023. The company is in the process of merging with OnKure, Inc. in an all-stock transaction, which is expected to close in", "url": "https://finance.yahoo.com/news/reneo-pharmaceuticals-reports-second-quarter-113500358.html", "source_name": "Market source", "published_at": "2024-08-13T20:39:09", "published_display": "13 Aug 2024 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger", "summary": "Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals on intellectual property matters concerning its definitive merger agreement with OnKure, Inc. This all-stock transaction will combine the two biopharmaceutical companies with a focus on advancing OnKure\u2019s oncology pip", "url": "https://www.wsgr.com/en/insights/wilson-sonsini-advises-reneo-pharmaceuticals-on-ip-matters-related-to-onkure-merger.html", "source_name": "Wilson Sonsini", "published_at": "2024-05-15T15:09:12", "published_display": "15 May 2024 15:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OnKure hitches Reneo's ride to Nasdaq in merger, with $65M PIPE to boot", "summary": "OnKure Therapeutics has merged with Reneo Pharmaceuticals in a reverse merger, bringing $120 million and a breast cancer treatment pipeline to the Nasdaq under the ticker \"OKUR.\" The deal includes a $65 million PIPE financing, with Reneo needing to maintain $55 million in cash, p", "url": "https://www.fiercebiotech.com/biotech/onkure-hitches-reneos-ride-nasdaq-65m-pipe-boot", "source_name": "Fierce Biotech", "published_at": "2024-05-13T10:36:00", "published_display": "13 May 2024 10:36", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reneo Pharmaceuticals and OnKure Announce Proposed Merger", "summary": "Reneo Pharmaceuticals and OnKure, a clinical-stage biopharmaceutical company, have announced a definitive merger agreement in an all-stock transaction. The combined entity, to be named OnKure Therapeutics, Inc., will focus on advancing OnKure's oncology pipeline, including its le", "url": "https://finance.yahoo.com/news/reneo-pharmaceuticals-onkure-announce-proposed-113500103.html", "source_name": "Market source", "published_at": "2024-05-13T08:10:03", "published_display": "13 May 2024 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 85, "total_relevant": 40, "sentiment_summary": {"positive": 10, "negative": 2, "neutral": 28, "score": 55, "total": 40, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 10.8, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 3.85, "count": 7}, {"event": "guidance", "label": "Guidance", "weight": 0.9, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 4.28, "latest_week": "2026-07-10", "one_week_move": -6.6, "four_week_move": 1.9, "twelve_week_move": -14.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.033976, "market_dynamics_buy_signal": false, "relative_strength": 12.836662, "fair_value_gap": -14.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.4325, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.6% over one week, +1.9% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "MarketBeat", "count": 2}, {"label": "Donan\u0131mHaber", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 7}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.6% over one week, +1.9% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to revenue forward of OnKure Therapeutics, Inc. \u2013 NASDAQ:OKUR"}], "updated_at": "2026-07-16T14:31:13.639438+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}